INT48840

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1993
Last Reported 2007
Negated 0
Speculated 1
Reported most in Abstract
Documents 8
Total Number 10
Disease Relevance 1.55
Pain Relevance 5.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Nkx2-2) nucleus (Nkx2-2) molecular_function (Nkx2-2)
transcription factor binding (Nkx2-2)
Anatomy Link Frequency
plasma 1
myometrium 1
neurons 1
bone marrow 1
bladder 1
Nkx2-2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
substance P 97 100.00 Very High Very High Very High
agonist 17 100.00 Very High Very High Very High
Calcitonin gene-related peptide 15 100.00 Very High Very High Very High
Somatostatin 12 100.00 Very High Very High Very High
antagonist 8 99.96 Very High Very High Very High
qutenza 15 99.60 Very High Very High Very High
Neuropeptide 23 98.56 Very High Very High Very High
Periaqueductal grey 5 91.04 High High
MU agonist 1 85.92 High High
Enkephalin 4 84.40 Quite High
Disease Link Frequency Relevance Heat
Vibrio Infection 40 91.44 High High
Urological Neuroanatomy 5 91.04 High High
Neuropathic Pain 14 77.44 Quite High
Overactive Bladder 3 75.00 Quite High
Hematological Disease 1 54.76 Quite High
Dysmenorrhea 2 54.56 Quite High
Nociception 20 50.00 Quite Low
Hyperalgesia 16 45.08 Quite Low
Injury 4 5.00 Very Low Very Low Very Low
Overdose 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) showed that both preprotachykinin (PPT)-I mRNA and the tachykinin neurokinin (NK)-1 mRNA expression in bone marrow cells significantly increased in capsaicin group, whereas the NK-2 mRNA expression was unchanged after capsaicin pretreatment.
Gene_expression (expression) of NK-2 mRNA in bone marrow associated with qutenza
1) Confidence 0.23 Published 2006 Journal Neurosci. Lett. Section Abstract Doc Link 16959413 Disease Relevance 0.05 Pain Relevance 0.75
The selective NK1, NK2 and NK3 agonists [Sar9,Met(O2)11]-Substance P (100 nM), GR 64349 (300-500 nM) and senktide (300 nM) also produced inward currents in subpopulations of neurons.
Gene_expression (produced) of NK2 in neurons associated with agonist and substance p
2) Confidence 0.21 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15921708 Disease Relevance 0.39 Pain Relevance 1.19
Among NK-3 receptor agonists, senktide (1-100 nmol/kg) was not effective; [MePhe7] NK-B (3-100 nmol/kg) induced bladder contraction, but the magnitude of the response was only 20 to 25% of that produced by NK-1 or NK-2 agonists.
Gene_expression (produced) of NK-2 in bladder associated with agonist
3) Confidence 0.20 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8383746 Disease Relevance 0.07 Pain Relevance 0.49
The receptors for neurokinin 1 (NK1-R), neurokinin 2 (NK2-R), and neurokinin 3 (NK3-R) are expressed and functionally active in the uterus, promoting strong contractions of the myometrium.
Gene_expression (expressed) of NK2-R in myometrium
4) Confidence 0.16 Published 2002 Journal Biol. Reprod. Section Abstract Doc Link 12390879 Disease Relevance 0.05 Pain Relevance 0.05
The cisplatin treatment significantly increased plasma somatostatin immunoreactivity and the expression of SSTR4 receptor detected both on the 11th and 22nd post-treatment days with no change in either CGRP, NK1, and NK2 receptor gene expression or plasma CGRP and substance P levels.
Gene_expression (expression) of NK2 in plasma associated with somatostatin, substance p and calcitonin gene-related peptide
5) Confidence 0.09 Published 2006 Journal Neuropeptides Section Abstract Doc Link 16343617 Disease Relevance 0.19 Pain Relevance 0.67
The levels of somatostatin receptor 4 (SSTR 4), neurokinin 1 (NK1), neurokinin 2 (NK2) and CGRP receptor expression were examined by quantitative real time polymerase chain reaction (RT-PCR) method, 11 and 22 days after the last cisplatin/vehicle dose.
Spec (examined) Gene_expression (levels) of NK2 associated with somatostatin and calcitonin gene-related peptide
6) Confidence 0.09 Published 2006 Journal Neuropeptides Section Abstract Doc Link 16343617 Disease Relevance 0.22 Pain Relevance 0.71
SR48968 and SR140333 thus appear to be potent tachykinin receptor antagonists, selective for intestinal receptors respectively of the NK2 and NK1 type.
Gene_expression (selective) of NK2 associated with antagonist
7) Confidence 0.09 Published 1995 Journal Life Sci. Section Abstract Doc Link 7529864 Disease Relevance 0 Pain Relevance 0.45
The levels of somatostatin receptor 4 (SSTR 4), neurokinin 1 (NK1), neurokinin 2 (NK2) and CGRP receptor expression were examined by quantitative real time polymerase chain reaction (RT-PCR) method, 11 and 22 days after the last cisplatin/vehicle dose.
Gene_expression (expression) of NK2 associated with somatostatin and calcitonin gene-related peptide
8) Confidence 0.07 Published 2006 Journal Neuropeptides Section Abstract Doc Link 16343617 Disease Relevance 0.22 Pain Relevance 0.70
Chinese Hamster Ovary cells stably expressing NK1, NK2 or NK3 receptors (a generous gift from Dr.
Gene_expression (expressing) of NK2 in Ovary
9) Confidence 0.02 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1878491 Disease Relevance 0.09 Pain Relevance 0.17
We found that SP-CTA produced equivalent effects on cAMP production in cultured cells expressing NK1 or NK2 receptors, but did not influence cAMP production in cells that expressed NK3 receptors or non-transfected cells.
Gene_expression (expressing) of NK2
10) Confidence 0.02 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1878491 Disease Relevance 0.26 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox